Shopping Cart
- Remove All
- Your shopping cart is currently empty
Rabeprazole (LY307640) is an H+/K+-ATPase inhibitor that inhibits cell proliferation in gastric epithelial cells by targeting STAT3-mediated glycolysis and can be used in the study of gastric ulcers.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
5 mg | $31 | In Stock | |
10 mg | $48 | In Stock | |
25 mg | $77 | In Stock | |
50 mg | $113 | In Stock |
Description | Rabeprazole (LY307640) is an H+/K+-ATPase inhibitor that inhibits cell proliferation in gastric epithelial cells by targeting STAT3-mediated glycolysis and can be used in the study of gastric ulcers. |
Targets&IC50 | UNH:0.3 μM (IC50) |
In vitro | Rabeprazole was administered to three gastric cancer cell lines, KATO III, MKN-28, and MKN-45, at a dosage of 0.2 mM under acidic conditions for 16 hours. The results showed that rabeprazole exerted a strong inhibitory effect on the proliferation of gastric cancer cells[2]. |
In vivo | The results of rabeprazole (10 mg/kg; oral administration; every 48 hours for 18 weeks) showed significantly lower serum calcium levels compared to the vehicle-treated group in Swiss albino mice[3]. |
Alias | LY307640 |
Molecular Weight | 359.44 |
Formula | C18H21N3O3S |
Cas No. | 117976-89-3 |
Smiles | COCCCOc1ccnc(CS(=O)c2nc3ccccc3[nH]2)c1C |
Relative Density. | 1.33 g/cm3 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | ||||||||||||||||||||
Solubility Information | DMSO: 5 mg/mL (13.91 mM), Sonication is recommended. | ||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||
DMSO
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.